Our results suggest that the PTX treatment and acquiring of inverse resistance to PTX and CDDP may turn off (e.g., via negatively regulated RUNX2) the osteomimic phenotype in ovarian cancers cells, at least in vitro. Here, RUNX2 is linked to ovarian cancer.